534 related articles for article (PubMed ID: 16059622)
1. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment.
Prince R; Sipos A; Hossain A; Syversen U; Ish-Shalom S; Marcinowska E; Halse J; Lindsay R; Dalsky GP; Mitlak BH
J Bone Miner Res; 2005 Sep; 20(9):1507-13. PubMed ID: 16059622
[TBL] [Abstract][Full Text] [Related]
2. Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.
Krege JH; Wan X
Bone; 2012 Jan; 50(1):161-4. PubMed ID: 22036910
[TBL] [Abstract][Full Text] [Related]
3. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.
Siris ES; Harris ST; Eastell R; Zanchetta JR; Goemaere S; Diez-Perez A; Stock JL; Song J; Qu Y; Kulkarni PM; Siddhanti SR; Wong M; Cummings SR;
J Bone Miner Res; 2005 Sep; 20(9):1514-24. PubMed ID: 16059623
[TBL] [Abstract][Full Text] [Related]
4. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
5. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis.
Lindsay R; Scheele WH; Neer R; Pohl G; Adami S; Mautalen C; Reginster JY; Stepan JJ; Myers SL; Mitlak BH
Arch Intern Med; 2004 Oct; 164(18):2024-30. PubMed ID: 15477438
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
7. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
[TBL] [Abstract][Full Text] [Related]
8. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial.
Reginster JY; Felsenberg D; Boonen S; Diez-Perez A; Rizzoli R; Brandi ML; Spector TD; Brixen K; Goemaere S; Cormier C; Balogh A; Delmas PD; Meunier PJ
Arthritis Rheum; 2008 Jun; 58(6):1687-95. PubMed ID: 18512789
[TBL] [Abstract][Full Text] [Related]
9. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Watts NB; Geusens P; Barton IP; Felsenberg D
J Bone Miner Res; 2005 Dec; 20(12):2097-104. PubMed ID: 16294263
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of teriparatide in increasing bone mineral density in postmenopausal women with osteoporosis--an Indian experience.
Sethi BK; Chadha M; Modi KD; Kumar KM; Mehrotra R; Sriram U
J Assoc Physicians India; 2008 Jun; 56():418-24. PubMed ID: 18822620
[TBL] [Abstract][Full Text] [Related]
11. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
Deal C; Omizo M; Schwartz EN; Eriksen EF; Cantor P; Wang J; Glass EV; Myers SL; Krege JH
J Bone Miner Res; 2005 Nov; 20(11):1905-11. PubMed ID: 16234962
[TBL] [Abstract][Full Text] [Related]
12. Vertebral fracture risk after once-weekly teriparatide injections: follow-up study of Teriparatide Once-Weekly Efficacy Research (TOWER) trial.
Sugimoto T; Shiraki M; Nakano T; Kishimoto H; Ito M; Fukunaga M; Hagino H; Sone T; Kuroda T; Nakamura T
Curr Med Res Opin; 2013 Mar; 29(3):195-203. PubMed ID: 23259702
[TBL] [Abstract][Full Text] [Related]
13. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
14. Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women.
Uusi-Rasi K; Semanick LM; Zanchetta JR; Bogado CE; Eriksen EF; Sato M; Beck TJ
Bone; 2005 Jun; 36(6):948-58. PubMed ID: 15878318
[TBL] [Abstract][Full Text] [Related]
15. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis.
Chen P; Miller PD; Delmas PD; Misurski DA; Krege JH
J Bone Miner Res; 2006 Nov; 21(11):1785-90. PubMed ID: 17002571
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures.
Aspenberg P; Genant HK; Johansson T; Nino AJ; See K; Krohn K; García-Hernández PA; Recknor CP; Einhorn TA; Dalsky GP; Mitlak BH; Fierlinger A; Lakshmanan MC
J Bone Miner Res; 2010 Feb; 25(2):404-14. PubMed ID: 19594305
[TBL] [Abstract][Full Text] [Related]
17. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures.
Hochberg MC; Thompson DE; Black DM; Quandt SA; Cauley J; Geusens P; Ross PD; Baran D;
J Bone Miner Res; 2005 Jun; 20(6):971-6. PubMed ID: 15883637
[TBL] [Abstract][Full Text] [Related]
18. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis.
Marcus R; Wang O; Satterwhite J; Mitlak B
J Bone Miner Res; 2003 Jan; 18(1):18-23. PubMed ID: 12510801
[TBL] [Abstract][Full Text] [Related]
19. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.
Neer RM; Arnaud CD; Zanchetta JR; Prince R; Gaich GA; Reginster JY; Hodsman AB; Eriksen EF; Ish-Shalom S; Genant HK; Wang O; Mitlak BH
N Engl J Med; 2001 May; 344(19):1434-41. PubMed ID: 11346808
[TBL] [Abstract][Full Text] [Related]
20. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS).
Eastell R; Nickelsen T; Marin F; Barker C; Hadji P; Farrerons J; Audran M; Boonen S; Brixen K; Gomes JM; Obermayer-Pietsch B; Avramidis A; Sigurdsson G; Glüer CC
J Bone Miner Res; 2009 Apr; 24(4):726-36. PubMed ID: 19049337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
